We continuously monitor the medication marketplace for impactful drug changes. It has come to our attention that there is a supply shortage of certain epinephrine auto-injectors, such as EpiPen® and authorized generics. Epinephrine is an emergency medication used to treat the effects of life-threatening allergic reactions caused by insect bites or stings, foods, medications, latex or other allergens. While epinephrine auto-injector supplies vary based on pharmacy location, AUVI-Q®, manufactured by kaléo, is readily available.
Epinephrine auto-injector manufacturer Impax Laboratories has not released an availability date for their product, citing good manufacturing practices as the reason for the shortage. Mylan Specialty, another manufacturer of an auto-injector product, is experiencing intermittent shortages due to manufacturing delays, making it difficult for patients to obtain this necessary emergency drug.
Generic epinephrine auto-injector products are preferred on EnvisionRx’s Standard and Select Formularies, while AUVI-Q is an EnvisionRx Standard and Select Formulary exclusion. As a result of this drug shortage, EnvisionRx is taking the following action to ensure patients can still obtain this life-saving medication until regular manufacturing resumes:
Beginning May 10, 2018, AUVI-Q was removed from the EnvisionRx formulary exclusion list, but will remain non-preferred, which will allow tier 3 access for patients to obtain one kit (two auto-injectors per kit) every 30 days.
EnvisionRx will continue to monitor the market closely and work with our pharmaceutical partners so that once supply has been restored, the formulary will revert to the original state. This will be communicated to plan sponsors accordingly.
EnvisionRx clients with questions should contact us or their account representatives.